Lateral lymph node dissection in clinical stage 2–3 mid and lower rectal cancer: is there a clinical benefit?

Marco Ettore Allaix, Alessandro Fichera, Mario Morino

Abstract

We have read with great interest the paper recently published by Fujita et al. (1) on Annals of Surgery reporting the 5-year oncologic results of a multicenter, randomized controlled, noninferiority trial comparing mesorectal excision with or without lateral lymph node dissection (LLND) for lower rectal cancer.